Research advances in cirrhotic cardiomyopathy
10.3969/j.issn.1001-5256.2016.05.047
- VernacularTitle:肝性心肌病的研究进展
- Author:
Shirong ZHANG
1
;
Dongfeng CHEN
Author Information
1. Department of Gastroenterology, Research Institute of Field Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, China
- Publication Type:Research Article
- Keywords:
cardiomyopathies;
liver cirrhosis;
diagnosis;
treatment;
review
- From:
Journal of Clinical Hepatology
2016;32(5):1005-1008
- CountryChina
- Language:Chinese
-
Abstract:
Cirrhotic cardiomyopathy (CCM) refers to the abnormalities in cardiac structure and function in patients with liver cirrhosis. The pathogenesis of CCM involves the apoptosis of cardiomyocytes, impaired β-receptors, and increased levels of cardiodepressant factors such as nitric oxide, carbon monoxide, endocannabinoids, bacterial endotoxins, and inflammatory mediators. At present, there are no unified diagnostic criteria for CCM, and a clinical diagnosis can be made based on clinical manifestation, plasma brain natriuretic peptide, N-terminal pro-brain natriuretic peptide, electrocardiographic findings, ultrasound findings, and the results of cardiac magnetic resonance imaging. The treatment of CCM involves controlling liver cirrhosis and protecting the myocardium, and the best therapeutic method is liver transplantation at the right time.
